欧洲前列腺癌筛查随机研究风险计算器:外部验证、变异性与临床意义
本研究前瞻性纳入1021例疑似前列腺癌拟行穿刺患者,对749例按ERSPC-RC(基于直肠指检的第3/4版)用连续2次PSA计算前列腺癌和显著前列腺癌风险。校准图显示两种PSA水平下判别能力相似,AUC分别为0.69和0.74;ERSPC-RC造成226例(30.2%)不必要穿刺并漏诊10例显著前列腺癌,风险计算器变异性为16%和20%。
要点
- 749例中检出前列腺癌251例(33.5%),显著前列腺癌133例(17.8%)。
- 连续2次PSA下ERSPC-RC的AUC为前列腺癌0.69、显著前列腺癌0.74。
- ERSPC-RC造成226例(30.2%)不必要穿刺,漏诊10例显著前列腺癌。
核心结论
- ERSPC-RC在本队列中连续2次PSA水平间表现高度相似,但风险计算器变异性与显著前列腺癌风险降低相关。
- 在本队列中使用ERSPC-RC会检出大量不必要穿刺,纳入ERSPC-RC可能有助于穿刺的临床决策。
研究设计与样本
- 前瞻性连续纳入1021例疑似前列腺癌拟行前列腺穿刺的患者,其中749例纳入分析。
- 按ERSPC-RC(基于直肠指检的第3/4版)对每例患者连续2次PSA检测计算前列腺癌和显著前列腺癌(Gleason评分≥7)风险。
- 采用校准图和受试者工作特征曲线下面积(AUC)分析预测效能,用Cohen kappa系数比较能力与变异性。
主要发现
- 749例中检出前列腺癌251例(33.5%),显著前列腺癌133例(17.8%)。
- 校准图显示两种PSA水平下平行性可接受且判别能力相似,前列腺癌AUC为0.69,显著前列腺癌AUC为0.74。
- ERSPC-RC造成226例(30.2%)不必要穿刺,并漏诊10例显著前列腺癌。
- 风险计算器变异性为前列腺癌16%、显著前列腺癌20%,较高的变异性与显著前列腺癌风险降低相关。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To externally validate the European Randomized Study of Screening for Prostate Cancer (ERSPC) risk calculator (RC) and to evaluate its variability between 2 consecutive prostate-specific antigen (PSA) values. MATERIALS AND METHODS: We prospectively catalogued 1021 consecutive patients before prostate biopsy for suspicion of prostate cancer (PCa). The risk of PCa and significant PCa (Gleason score ≥7) from 749 patients was calculated according to ERSPC-RC (digital rectal examination-based version 3 of 4) for 2 consecutive PSA tests per patient. The calculators' predictions were analyzed using calibration plots and the area under the receiver operating characteristic curve (area under the curve). Cohen kappa coefficient was used to compare the ability and variability. RESULTS: Of 749 patients, PCa was detected in 251 (33.5%) and significant PCa was detected in 133 (17.8%). Calibration plots showed an acceptable parallelism and similar discrimination ability for both PSA levels with an area under the curve of 0.69 for PCa and 0.74 for significant PCa. The ERSPC showed 226 (30.2%) unnecessary biopsies with the loss of 10 significant PCa. The variability of the RC was 16% for PCa and 20% for significant PCa, and a higher variability was associated with a reduced risk of significant PCa. CONCLUSION: We can conclude that the performance of the ERSPC-RC in the present cohort shows a high similitude between the 2 PSA levels; however, the RC variability value is associated with a decreased risk of significant PCa. The use of the ERSPC in our cohort detects a high number of unnecessary biopsies. Thus, the incorporation of ERSPC-RC could help the clinical decision to carry out a prostate biopsy.
引用
- Gómez-Gómez E, Carrasco-Valiente J, Blanca-Pedregosa A, et al. European Randomized Study of Screening for Prostate Cancer Risk Calculator: External Validation, Variability, and Clinical Significance. Urology. 2016. PMID: 27840252. doi:10.1016/j.urology.2016.11.004
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。